BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17227901)

  • 1. The use of bisphosphonates in elderly cancer patients.
    Gridelli C
    Oncologist; 2007 Jan; 12(1):62-71. PubMed ID: 17227901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are bisphosphonates the suitable anticancer drugs for the elderly?
    Santini D; Fratto ME; Galluzzo S; Vincenzi B; Tonini G
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):83-94. PubMed ID: 18692400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avascular mandibular osteonecrosis in association with bisphosphonate therapy: a report on four patients.
    Friedrich RE; Blake FA
    Anticancer Res; 2007; 27(4A):1841-5. PubMed ID: 17649782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases.
    Grant BT; Amenedo C; Freeman K; Kraut RA
    J Oral Maxillofac Surg; 2008 Feb; 66(2):223-30. PubMed ID: 18201600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients.
    Body JJ; Coleman R; Clezardin P; Ripamonti C; Rizzoli R; Aapro M;
    Eur J Cancer; 2007 Mar; 43(5):852-8. PubMed ID: 17258449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis.
    Wilkinson GS; Kuo YF; Freeman JL; Goodwin JS
    J Natl Cancer Inst; 2007 Jul; 99(13):1016-24. PubMed ID: 17596574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
    Grewal VS; Fayans EP
    Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of bisphosphonates in cancer patients.
    Wu S; Dahut WL; Gulley JL
    Acta Oncol; 2007; 46(5):581-91. PubMed ID: 17562434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy of bone metastases in breast cancer patients.
    Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
    Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing metastatic bone pain: the role of bisphosphonates.
    Gralow J; Tripathy D
    J Pain Symptom Manage; 2007 Apr; 33(4):462-72. PubMed ID: 17397707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteonecrosis of the jaw due to bisphosphonates.
    Prescrire Int; 2008 Oct; 17(97):202-3. PubMed ID: 19536938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse effects of bisphosphonates: current issues.
    Diel IJ; Bergner R; Grötz KA
    J Support Oncol; 2007; 5(10):475-82. PubMed ID: 18240669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates.
    Lobato JV; Rodrigues JM; Cavaleiro MV; Lobato JM; Xavier L; Santos JD; Maurício AC
    Acta Med Port; 2007; 20(2):185-92. PubMed ID: 17868526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate-induced osteonecrosis of the jaw.
    Krueger CD; West PM; Sargent M; Lodolce AE; Pickard AS
    Ann Pharmacother; 2007 Feb; 41(2):276-84. PubMed ID: 17299010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis.
    Costa L
    Breast; 2007 Dec; 16 Suppl 3():S16-20. PubMed ID: 18032044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma?
    Siddiqi A; Payne AG; Zafar S
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Sep; 108(3):e1-8. PubMed ID: 19570696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of bisphosphonates in cancer therapy.
    Lüftner D; Henschke P; Possinger K
    Anticancer Res; 2007; 27(4A):1759-68. PubMed ID: 17649770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral bisphosphonate therapy and osteonecrosis of the jaw: what to tell the concerned patient.
    Koka S; Clarke BL; Amin S; Gertz M; Ruggiero SL
    Int J Prosthodont; 2007; 20(2):115-22. PubMed ID: 17455429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.